RE:RE:RE:RE:A PILL TO COMPETE WITH PCSK9'sFurther to Tundup and Bear's post; According to Stockhouse Esperion's market cap is about $1.5B. Give that to RVX and you have a roughly $17 stock. Probably similar potential opportunities in, broadly, the "cholesterol" space although I haven't really looked into any projections for Esperion. RVX would seem to have a few more potential opportunities related to kidney disease etc but all in all I think there is a huge disconnect in relative price between two "cholesterol" drugs soon to be entering ph3